Activities of Ángela VALLINA related to 2016/2057(INI)
Shadow opinions (1)
OPINION on the EU options for improving access to medicines
Amendments (12)
Amendment 1 #
Draft opinion
Paragraph 1
Paragraph 1
1. Believes that the opinions of European citizens voiced by petitioning the European Parliament are fundamentally important in signalling to the European legislator issues that citizens feel concerned about, particularly the lack of access to, high prices of and inadequate distribution of medicines, the impact of the economic crisisneoliberal policies and of cuts to public investment in health which have increased significantly since the economic crisis, the latter’s impact on medical and pharmaceutical care, and issues regarding marketing procedures and patents for medicinal products;
Amendment 12 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls for universal access to good quality, free public health services to be ensured in the Member States as the sole way of ensuring a high level of human health protection to be ensuredfor the whole population in the definition and implementation of all the Union’s policies and activities, as required by Article 35 of the Charter of Fundamental Rights of the European Union;
Amendment 15 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Reiterates that the right to health is a human right recognised both in the Universal Declaration of Human Rights and in the International Covenant on Economic, Social and Cultural Rights and that this right concerns all Member States given that they have ratified international human rights treaties that recognise the right to health; points out that for this right to be guaranteed, access to medicine, among other factors, has to be ensured;
Amendment 25 #
Draft opinion
Paragraph 3
Paragraph 3
3. Deplores the fact that there are 18 million people without access to health care or medicines, whose human rights are being violated on a daily basis; finds it alarming that there are 25 000 annual deaths in the EU due to lack of effective antibiotics and that many people die because they do not have access to or cannot pay the high cost of treatments such as the HIV/AIDS antiretroviral drugs or drugs to treat hepatitis C;
Amendment 41 #
Draft opinion
Paragraph 5
Paragraph 5
Amendment 63 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Demands the urgent adoption of new formulas for public patents that would avoid the disproportionate profits made currently by the pharmaceutical industry, such as an EU and worldwide renegotiation of access to medicines, which would include the possibility of mandatory licences;
Amendment 65 #
Draft opinion
Paragraph 7 b (new)
Paragraph 7 b (new)
7b. Calls for an investigation to be opened into whether the high prices for new hepatitis C drugs are in breach of EU procurement law;
Amendment 66 #
Draft opinion
Paragraph 7 c (new)
Paragraph 7 c (new)
7c. Demands greater transparency in regard to public procurement prices for medicines and proposes that a central purchasing body be established at EU level;
Amendment 90 #
Draft opinion
Paragraph 10
Paragraph 10
10. Calls on the Member States to establish a pooled public platform for R&D financed by all states via a minimum contribution of 0.01 % of their GDP.
Amendment 95 #
Draft opinion
Paragraph 10 a (new)
Paragraph 10 a (new)
10a. Calls for an emergency health recovery fund to be set up at EU level for people in the EU Member States who are suffering from pathologies such as hepatitis C or HIV/AIDS;
Amendment 96 #
Draft opinion
Paragraph 10 b (new)
Paragraph 10 b (new)
10b. Urges the establishment of a plan to study and collect data on the prevalence of hepatitis C in the EU, and to promote action in research, funding and recommendations that will enable an early diagnosis thereof at EU level; calls for action in research, funding and recommendations that will ensure early diagnosis, as well as for standards to be adopted and good practices exchanged in the Member States;
Amendment 97 #
Draft opinion
Paragraph 10 c (new)
Paragraph 10 c (new)
10c. Proposes that a parliamentary working party be set up to examine the research and development costs of medicines, and their sale price;